-
Sotorasib is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor, which inhibits tumor growth in mice. -
MC2590 is a potent pyridine-containing HDAC inhibitor and modulates pro- and anti-apoptotic microRNAs toward apoptosis induction. -
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TWEAK with potent antitumor activity. -
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells. -
Tigatuzumab, a humanized IgG1 anti-DR5 monoclonal antibody, is aTRAIL-R2 agonist, with potent anticancer effects. -
LY3177833 is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer -
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7. -
AZ31 is a potent, highly selective, and orally active ATM inhibitor, and is also a potent radiosensitizer in vitro. -
G12Si-5, a potent, selective and reversible covalent inhibitor of the K-Ras G12S, can be used for the research of cancer. -
LDN-211904 oxalate is a potent and selective EphB3 inhibitor and combines with cetuximab can overcome cetuximab resistance.
Categories
Diseases
Others
Archives
- March 2023 (1)
- February 2023 (1)
- January 2023 (3)
- November 2022 (1)
- October 2022 (2)
- September 2022 (1)
- July 2022 (1)
- June 2022 (1)
- May 2022 (1)
- February 2022 (1)
- January 2022 (3)
- November 2021 (2)
- October 2021 (1)
- September 2021 (1)
- June 2021 (1)
- May 2021 (2)
- April 2021 (2)
- March 2021 (1)
- February 2021 (2)
- November 2020 (2)
- October 2020 (1)
- July 2020 (1)
- October 2019 (2)
- August 2019 (1)
- June 2019 (3)
- May 2019 (2)
- April 2019 (1)
